These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 17135991

  • 1. Glad for what TADS adds, but many TADS grads still sad.
    Brent DA.
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1461-4. PubMed ID: 17135991
    [No Abstract] [Full Text] [Related]

  • 2. After TADS, can we measure up, catch up, and ante up?
    Jensen PS.
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1456-60. PubMed ID: 17135990
    [No Abstract] [Full Text] [Related]

  • 3. Turning darkness into light. A new landmark study on the treatment of adolescent depression. Comments on the TADS study.
    Apter A, Kronenberg S, Brent D.
    Eur Child Adolesc Psychiatry; 2005 May; 14(3):113-6. PubMed ID: 15959656
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of depression treatment for adolescents.
    Norquist G, McGuire TG, Essock SM.
    Am J Psychiatry; 2008 May; 165(5):549-52. PubMed ID: 18450932
    [No Abstract] [Full Text] [Related]

  • 5. Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study.
    Scott K, Lewis CC, Marti CN.
    J Am Acad Child Adolesc Psychiatry; 2019 Mar; 58(3):319-328. PubMed ID: 30768414
    [Abstract] [Full Text] [Related]

  • 6. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
    March J, Silva S, Vitiello B, TADS Team.
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1393-403. PubMed ID: 17135984
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacological management of treatment-resistant pediatric depression.
    Kratochvil CJ, Wagner KD, Emslie G, March J.
    J Am Acad Child Adolesc Psychiatry; 2005 Feb; 44(2):198-200. PubMed ID: 15689734
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS).
    Vitiello B, Kratochvil CJ, Silva S, Curry J, Reinecke M, Pathak S, Waslick B, Hughes CW, Prentice ED, May DE, March JS.
    J Am Acad Child Adolesc Psychiatry; 2007 Dec; 46(12):1642-50. PubMed ID: 18030086
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
    Kennard B, Silva S, Vitiello B, Curry J, Kratochvil C, Simons A, Hughes J, Feeny N, Weller E, Sweeney M, Reinecke M, Pathak S, Ginsburg G, Emslie G, March J, TADS Team.
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1404-11. PubMed ID: 17135985
    [Abstract] [Full Text] [Related]

  • 15. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J.
    Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
    [Abstract] [Full Text] [Related]

  • 16. Acute time to response in the Treatment for Adolescents with Depression Study (TADS).
    Kratochvil C, Emslie G, Silva S, McNulty S, Walkup J, Curry J, Reinecke M, Vitiello B, Rohde P, Feeny N, Casat C, Pathak S, Weller E, May D, Mayes T, Robins M, March J, TADS Team.
    J Am Acad Child Adolesc Psychiatry; 2006 Dec; 45(12):1412-8. PubMed ID: 17135986
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
    Treatment for Adolescents With Depression Study (TADS) TeamDepartment of Psychiatry and Behavioral Sciences and the Duke Clinical Research Institute at Duke University Medical Center, Durham, NC 27705, USA. john.march@duke.edu, March J, Silva S, Curry J, Wells K, Fairbank J, Burns B, Domino M, Vitiello B, Severe J, Riedal K, Goldman M, Feeny N, Findling R, Stull S, Baab S, Weller EB, Robbins M, Weller RA, Jessani N, Waslick B, Sweeney M, Dublin R, Walkup J, Ginsburg G, Kastelic E, Koo H, Kratochvil C, May D, LaGrone R, Vaughan B, Albano AM, Hirsch GS, Podniesinki E, Chu A, Reincecke M, Leventhal B, Rogers G, Jacobs R, Pathak S, Wells J, Lavanier SA, Danielyan A, Rohde P, Simons A, Grimm J, Frank S, Emslie G, Kennard B, Hughes C, Mayes TL, Rosenberg D, Benazon N, Butkus M, Bartoi M.
    Am J Psychiatry; 2009 Oct; 166(10):1141-9. PubMed ID: 19723787
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R.
    Health Technol Assess; 2008 May; 12(14):iii-iv, ix-60. PubMed ID: 18462573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.